Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA To Contact Sponsors Of Over 100 Drugs At Risk Of Shortage Post Brexit

Executive Summary

The European Medicines Agency’s survey on industry’s preparedness for Brexit has raised serious concerns about the continued supply of 108 drugs that have manufacturing operations based solely in the UK.

Advertisement

Related Content

Brexit: Number Of Drugs At Risk Of Shortage Cut From 108 to 39
BIA Wants More Brexit Clarity From UK Regulator As Odds Narrow On ‘No-Deal’ Outcome
Dealing With Brexit: EMA Offers Firms Advice On More Thorny Questions
EMA To Re-Prioritize Tasks To Cope With ‘Higher Than Expected’ Staff Losses
Industry Response To Brexit Survey Key For Future Planning, Says EMA
EU Regulators Urge Pharma To Share Their Brexit Plans
Brexit: Advising Companies To Prepare For Only The Worst Case Scenario Is Premature, Says BIA

Topics

Advertisement
UsernamePublicRestriction

Register

PS123473

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel